SCHEMBL465060

SCHEMBL465060

CCCCS(=O)(=O)ON1CCOCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
POLB P06746 2/20 0.39
HTT P42858 1/20 0.36
ALDH1A1 P00352 4/20 0.35
MAPK1 P28482 2/20 0.35
CYP1A2 P05177 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
HTR2A P28223 1/20 0.35
SCN1A P35498 1/20 0.35
HTR2B P41595 1/20 0.35
KCNH2 Q12809 1/20 0.35
SCN2A Q99250 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
SCN3A Q9NY46 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
USP2 O75604 1/20 0.34
MAPT P10636 2/20 0.33
CA12 O43570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28752430 0.93 THRB (0.38) LMNASMN1; SMN2POLBHTTALDH1A1
SCHEMBL546851 0.89 ALDH1A1 (0.39) LMNASMN1; SMN2POLBHTTALDH1A1
SCHEMBL905562 0.87 ALDH1A1 (0.38) LMNASMN1; SMN2POLBHTTALDH1A1
SCHEMBL27669796 0.85 CA12 (0.41) LMNASMN1; SMN2POLBALDH1A1USP2
SCHEMBL6048632 0.83 L3MBTL1 (0.35) LMNASMN1; SMN2POLBHTTALDH1A1
SCHEMBL465094 0.83 CA12 (0.39) LMNASMN1; SMN2HTTALDH1A1MAPK1
SCHEMBL9009668 0.81 L3MBTL1 (0.37) LMNASMN1; SMN2POLBHTTALDH1A1
SCHEMBL27424013 0.81 CA12 (0.38) LMNASMN1; SMN2HTTALDH1A1MAPK1
Water SCHEMBL27714982 0.81 CA12 (0.38) LMNASMN1; SMN2HTTALDH1A1MAPK1
SCHEMBL27480394 0.81 CA12 (0.38) LMNASMN1; SMN2HTTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102766128-A Process for production of delta-9-tetrahydrocannabinol AMR TECHNOLOGY INC 2012-11-07 CN claimed
CN-102380100-A Stable protease composition TROBIO AB 2012-03-21 CN claimed
EP-1637141-B1 Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease TROBIO AB (SE) 2011-11-16 EP claimed
WO-2011131234-A1 SENSOR APPARATUS ADAPTED TO BE INCORPORATED IN A GARMENT WEARABLE INFORMATION TECHNOLOGIES, S.L. (WEARTECH) (ES) 2011-10-27 WO claimed
US-20090136474-A1 Stabilized Protease Composition TROBIO AB (SE) 2009-05-28 US claimed
CN-101316832-A Method for producing delta-9-tetrahydrocannabinol AMR TECHNOLOGY INC (US) 2008-12-03 CN claimed
CN-101272790-A Stable protease compositions TROBIO AB (SE) 2008-09-24 CN claimed
WO-2007035143-A1 STABILIZED PROTEASE COMPOSITION TROBIO AB (SE) 2007-03-29 WO claimed
EP-1637141-A1 Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease Trobio AB (SE) 2006-03-22 EP claimed
US-8574569-B2 Stabilized protease composition TROBIO AB (SE) 2013-11-05 US disclosed
US-20130157339-A1 STABILIZED PROTEASE COMPOSITION TROBIO AB (SE) 2013-06-20 US disclosed
US-8394372-B2 Stabilized protease composition TROBIO AB (SE) 2013-03-12 US disclosed
CN-102766128-A Process for production of delta-9-tetrahydrocannabinol AMR TECHNOLOGY INC 2012-11-07 CN disclosed
CN-102380100-A Stable protease composition TROBIO AB 2012-03-21 CN disclosed
WO-2011131234-A1 SENSOR APPARATUS ADAPTED TO BE INCORPORATED IN A GARMENT WEARABLE INFORMATION TECHNOLOGIES, S.L. (WEARTECH) (ES) 2011-10-27 WO disclosed
US-20090136474-A1 Stabilized Protease Composition TROBIO AB (SE) 2009-05-28 US disclosed
CN-101316832-A Method for producing delta-9-tetrahydrocannabinol AMR TECHNOLOGY INC (US) 2008-12-03 CN disclosed
CN-101272790-A Stable protease compositions TROBIO AB (SE) 2008-09-24 CN disclosed
WO-2007035143-A1 STABILIZED PROTEASE COMPOSITION TROBIO AB (SE) 2007-03-29 WO disclosed
EP-1637141-A1 Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease Trobio AB (SE) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136474-A1 Stabilized Protease Composition SERPINE1, SERPINB1, CTRL LMNA 505/4885SMN1; SMN2 655/4885POLB 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.